PLA2G4A

Across TCGA pan-cancer cohorts, PLA2G4A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PLA2G4A data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLA2G4A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLA2G4A expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where PLA2G4A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.492	0.275	<.001	75	view →
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	31	view →
GBM	OS	Tertile	All	0.850	0.970	.016	9	view →
UCEC	OS	Median	All	0.980	0.826	.002	8	view →
LUAD	OS	Median	III,IV	1.000	0.661	.004	6	view →
LSCC	DFS	Median	II,III,IV	0.828	0.541	.004	4	view →
HNSC	DFS	Median	II,III,IV	0.728	0.562	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PLA2G4A–PDAC (OS)

Open the PDAC breakdown →